ライフサイエンスコーパス: osteonecrosis

1 lymorphisms were associated with symptomatic osteonecrosis.

2 (11.7%) children with GG genotype, developed osteonecrosis.

3 genetic variation may contribute to risk of osteonecrosis.

4 tive therapeutic target for the treatment of osteonecrosis.

5 dysplasias reminiscent of osteoarthritis and osteonecrosis.

6 intestinal events; malignant conditions; and osteonecrosis.

7 dicted solely by lesion size at diagnosis of osteonecrosis.

8 (range, 0.5 to 8.6 years) after diagnosis of osteonecrosis.

9 and klotho were associated with sickle cell osteonecrosis.

10 tify ALL patients at highest risk to develop osteonecrosis.

11 y, pathogenesis, diagnosis, and treatment of osteonecrosis.

12 utual adjustment, no ARV was associated with osteonecrosis.

13 the femoral head or, better yet, preventing osteonecrosis.

14 ents with clinical suspicion of femoral head osteonecrosis.

15 h detection of and determining the extent of osteonecrosis.

16 on of apoptotic osteocytes may contribute to osteonecrosis.

17 oid treatment, and no other risk factors for osteonecrosis.

18 bidities contribute to risk of fractures and osteonecrosis.

19 critical role in the glucocorticoid-induced osteonecrosis.

20 ng induction and experienced excess rates of osteonecrosis.

21 ated with the glomerular filtration rate and osteonecrosis.

22 ide new insights into the pathophysiology of osteonecrosis.

23 emia (ALL) and their major adverse effect is osteonecrosis.

24 tify genetic and nongenetic risk factors for osteonecrosis.

25 ipants were followed to assess fractures and osteonecrosis.

26 ociation may allow interventions to decrease osteonecrosis.

27 marrow edema syndrome (TBMES) and avascular osteonecrosis.

28 ical malignancies, are at risk of developing osteonecrosis.

29 t occurring in knees without any evidence of osteonecrosis.

30 control group in a pig model of femoral head osteonecrosis.

31 e dose modification would reduce the risk of osteonecrosis.

32 idence/1000 PYFU 7.2; 95% CI 6.6-7.7) and 89 osteonecrosis (1.0; 0.8-1.3).

33 ing the efficacy of ACTH in preventing human osteonecrosis, a devastating complication of glucocortic

34 rrent knowledge of bisphosphonate-associated osteonecrosis, a new oral complication in oncology.

35 To address osteonecrosis, a novel alternate-week schedule of dexame

36 to define possible genetic risk factors for osteonecrosis among children treated for newly diagnosed

37 increased prevalence for the development of osteonecrosis among females.

38 fit and was associated with a higher risk of osteonecrosis among participants 10 years and older.

39 hether 12 polymorphisms were associated with osteonecrosis among patients 10 years and older treated

40 antibody might promote the manifestation of osteonecrosis and compromise oral healing capacity.

41 r bone complications including fractures and osteonecrosis and for reduced or delayed response to enz

42 d, in older children, increased incidence of osteonecrosis and fracture.

43 dexamethasone exposure were associated with osteonecrosis and may be linked by inherited genomic var

44 pensated hypothyroidism in 9 patients (10%), osteonecrosis and moderate osteopenia in 2 patients each

45 There were no cases of incident drug-induced osteonecrosis and only 1 case of femoral shaft fracture

46 ed either to intramedullary hematopoiesis or osteonecrosis and osteomyelitis.

47 ting event in the genesis of steroid-induced osteonecrosis and provides a basis for future investigat

48 ations of HIV and HAART, such as osteopenia, osteonecrosis, and infection continue to be a concern.

49 performance status scores, incidence of jaw osteonecrosis, and kidney dysfunction did not differ sig

50 sterol (P = .02) associated with symptomatic osteonecrosis, and severe (grade 3 or 4) osteonecrosis w

51 dentify individuals who are at high risk for osteonecrosis, and thus allow earlier and more effective

52 ce imaging of both hips was used to diagnose osteonecrosis, and was performed at similar times from t

53 ifferentiation, were associated with risk of osteonecrosis as well as with lower albumin and higher c

54 ing earlier in the diagnosis of femoral head osteonecrosis, as well as its more widespread use in pat

55 ensitivity to asparaginase, hyperlipidaemia, osteonecrosis, asparaginase-associated pancreatitis, art

56 Osteonecrosis-associated glutamate receptor variants wer

57 1 years, the overall cumulative incidence of osteonecrosis at 5 years was 7.7% (SE 0.9), correlating

58 y-six (92%) of 50 patients with femoral head osteonecrosis at both examinations were placed in the ap

59 e increased in acute lymphoblastic leukemia, osteonecrosis became an increasingly frequent complicati

60 ether screening could identify extensive hip osteonecrosis before symptom development.

61 Bisphosphonate-associated osteonecrosis (BON) of the jaw is a growing concern in t

62 antly improved ONFH-induced symptoms such as osteonecrosis, bone loss, reduction in vessel perfusion,

63 osteroid use is an important risk factor for osteonecrosis, but its pathogenesis is likely multifacto

64 buminuria, leg ulcers, priapism, stroke, and osteonecrosis) by clinical examination, laboratory tests

65 Osteonecrosis can develop spontaneously or after an inva

66 ll disease, clinical complications including osteonecrosis can vary in frequency and severity, presum

67 o the two leading etiologic associations for osteonecrosis: corticosteroids and alcohol.

68 llowed, documented, and the treatment of the osteonecrosis described.

69 e persisted in the region, and a new site of osteonecrosis developed on the contralateral side of the

70 ay in healing may increase the likelihood of osteonecrosis developing in already-compromised bone.

71 Patterns for TBMES and osteonecrosis did not overlap.

72 In the most severe cases of osteonecrosis, end-stage lesions consisted of fully occl

73 y therefore have utility in the treatment of osteonecrosis, especially in aged patients.

74 Hip osteonecrosis frequently complicates treatment with gluc

75 rs, plesiosaurs, and humans develop dysbaric osteonecrosis from end-artery nitrogen embolism ("the be

76 oral resolution can allow differentiation of osteonecrosis from TBMES in hip and knee joints.

77 Osteonecrosis has been reported to occur occasionally am

78 Prior studies on the genetics of osteonecrosis have focused on patients >/=10 years of ag

79 Putative risk factors for osteonecrosis have included being female, white race, an

80 e receptor GRIN3A locus) was associated with osteonecrosis (hazard ratio = 2.03; P = 3.59 x 10(-7)).

81 ory has developed a model of steroid-induced osteonecrosis in BALBcJ mice which reflects clinically r

82 adults showed a size-related development of osteonecrosis in chevron and rib bone articulations, del

83 first evaluation of genetic risk factors for osteonecrosis in children <10 years.

84 imple dose modification, reduces the risk of osteonecrosis in children and adolescents given intensif

85 To evaluate risk factors for osteonecrosis in human immunodeficiency virus (HIV)-infe

86 The degree of risk for osteonecrosis in patients taking oral bisphosphonates, s

87 ation, oxidant stress, bone metabolism) with osteonecrosis in patients with sickle cell disease.

88 ting clinical joint outcomes of femoral head osteonecrosis in pediatric patients with leukemia or lym

89 may provide insight into the pathogenesis of osteonecrosis in sickle cell disease, help identify indi

90 t predictor of clinical joint outcome of hip osteonecrosis in survivors of pediatric hematologic mali

91 d in hundreds of cases to be associated with osteonecrosis in the jaw.

92 There was one documented case of osteonecrosis in the zoledronic acid group.

93 orphism (rs6092) was associated with risk of osteonecrosis in univariate (P = .002; odds ratio = 2.79

94 subchondral area was found between TBMES and osteonecrosis; in joints with osteonecrosis, this was co

95 elayed intensification significantly reduced osteonecrosis incidence compared with continuous dexamet

96 e race (OR, 11.1; P =.037), host factors for osteonecrosis included the vitamin D receptor FokI start

97 roids remained significantly associated with osteonecrosis, independently of HIV disease stage and pr

98 Studies concerning the treatment of osteonecrosis indicate that most preservative (ie, joint

99 Osteonecrosis is a dose-limiting toxicity in the treatme

100 Osteonecrosis is a severe glucocorticoid-induced complic

101 Bisphosphonate-associated osteonecrosis is characterised by the unexpected appeara

102 Juvenile femoral head osteonecrosis is due to disruption of blood supply which

103 ans, raised a concern that the prevalence of osteonecrosis is increasing.

104 Lesion size of osteonecrosis is the best predictor of clinical joint ou

105 rticoid therapy, screening for extensive hip osteonecrosis is unnecessary because their risk is low a

106 Osteonecrosis joints showed a subchondral area with low

107 7.2%]) of 339 HIV-infected participants had osteonecrosis lesions on magnetic resonance imaging, and

108 The future treatment of osteonecrosis may involve genetic or cell-based therapie

109 ate MTT, which was only found in joints with osteonecrosis, mean +/- standard deviation PF was 18.9 m

110 25 patients with and the 39 patients without osteonecrosis (median, 447 days and 443 days, respective

111 effects, including infection, bone fracture, osteonecrosis, mood and behaviour problems, and myopathy

112 Among HIV-infected participants, osteonecrosis occurred more frequently in those who used

113 Osteonecrosis of the capital femoral epiphysis is a sign

114 resonance imaging scans of 80 patients with osteonecrosis of the capital femoral epiphysis.

115 lucocorticoids in which treated mice develop osteonecrosis of the distal femoral epiphysis when admin

116 Osteonecrosis of the femoral head (ONFH) primarily resul

117 se, loss of blood supply results in ischemic osteonecrosis of the femoral head (ONFH).

118 is an important event in steroid-associated osteonecrosis of the femoral head (SONFH).

119 orticotropic hormone (ACTH) protects against osteonecrosis of the femoral head induced by depot methy

120 r, but their effect on risk of fractures and osteonecrosis of the femoral head is less understood.

121 s' disease (Perthes' disease) is a childhood osteonecrosis of the hip for which the disease determina

122 The diagnosis of symptomatic osteonecrosis of the hip in two of the authors' patients

123 e between primary diagnosis and diagnosis of osteonecrosis of the hip was 1.7 years (range, 0.1 to 17

124 Osteonecrosis of the hip, as documented by magnetic reso

125 py for acute lymphoblastic leukemia (ALL) is osteonecrosis of the hip.

126 HIV have an unexpectedly high occurrence of osteonecrosis of the hip.

127 el alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozuma

128 as associated with higher rates of confirmed osteonecrosis of the jaw (35 [4%]) than was clodronic ac

129 Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is a morbid bone disease

130 etio-pathogenesis of bisphosphonate-induced osteonecrosis of the jaw (BONJ).

131 Bisphosphonate-related osteonecrosis of the jaw (BRONJ) commonly occurs in indi

132 Bisphosphonate-associated osteonecrosis of the jaw (BRONJ) is a feared side effect

133 is is associated with bisphosphonate-related osteonecrosis of the jaw (BRONJ).

134 acid group, there were 17 confirmed cases of osteonecrosis of the jaw (cumulative incidence, 1.1%; 95

135 Medication-related osteonecrosis of the jaw (MRONJ), although initially bel

136 The incidence of osteonecrosis of the jaw (ONJ) in the population is low,

137 Osteonecrosis of the jaw (ONJ), a side-effect of bisphos

138 ta regarding atrial fibrillation, bone pain, osteonecrosis of the jaw (ONJ), atypical fractures, and

139 issues, inappropriate femoral fractures, and osteonecrosis of the jaw (ONJ), the pathophysiological m

140 ded the guideline to include a discussion of osteonecrosis of the jaw (ONJ).

141 dical benefits seem to outweigh the risk for osteonecrosis of the jaw (ONJ).

142 teriparatide administration in patients with osteonecrosis of the jaw (ONJ).

143 ssociated with the occasional development of osteonecrosis of the jaw (ONJ).

144 sion under Adalimumab therapy presented with osteonecrosis of the jaw after suspended oral and intrav

145 tients analysable for safety, three (1%) had osteonecrosis of the jaw and 15 (5%) hypocalcaemia.

146 Osteonecrosis of the jaw and atypical femur fractures ha

147 ents were similar in both groups, except for osteonecrosis of the jaw and hypocalcaemia.

148 or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the

149 Risk factors for osteonecrosis of the jaw and renal impairment should be

150 te proactive adjudication of every potential osteonecrosis of the jaw by an international expert pane

151 33 cases of suspected osteonecrosis of the jaw have been reported, with 26 con

152 d case series described clinical features of osteonecrosis of the jaw in patients with cancer who wer

153 There was one possible case of osteonecrosis of the jaw in the clodronate group.

154 eons described 104 patients with cancer with osteonecrosis of the jaw in the medical literature and i

155 Osteonecrosis of the jaw occurred at similarly low rates

156 Osteonecrosis of the jaw occurred infrequently (2.0%, de

157 33 (5%) patients on denosumab developed osteonecrosis of the jaw versus none on placebo.

158 A recommendation regarding osteonecrosis of the jaw was added.

159 2%] of 697 vs 172 [24%] of 704) but rates of osteonecrosis of the jaw were low in both groups (nine [

160 Seven cases of osteonecrosis of the jaw were reported in the long-term

161 No cases of osteonecrosis of the jaw were reported, and no adverse e

162 y an international expert panel, no cases of osteonecrosis of the jaw were reported.

163 Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures

164 res indicate worse disability), incidence of osteonecrosis of the jaw, kidney dysfunction, skeletal m

165 zoledronic acid, who unexpectedly developed osteonecrosis of the jaw.

166 ons, tumor metastasis and infections such as osteonecrosis of the jaw.

167 ust be instituted to avoid renal toxicity or osteonecrosis of the jaw.

168 e pathogenesis of the bisphosphonate-induced osteonecrosis of the jaw.

169 ic sites, such as the bisphosphonate-related osteonecrosis of the jaw.

170 Osteonecrosis of the jaws (ONJ) is a rare but severe com

171 udies have linked bisphosphonate therapy and osteonecrosis of the jaws (ONJ), but neither causality n

172 Despite these benefits, osteonecrosis of the jaws has recently emerged as a sign

173 Osteonecrosis of the jaws is a recently described advers

174 ing bisphosphonates are at greatest risk for osteonecrosis of the jaws; these patients represent 94%

175 Osteonecrosis of the symphysis pubis was seen in six of

176 Osteonecrosis (ON) is a potentially serious complication

177 ely evaluated the incidence of fractures and osteonecrosis (ON) on two consecutive pediatric ALL prot

178 2 hips of 91 patients who had no evidence of osteonecrosis or diseases involving bone marrow, no hist

179 dure for the treatment of painful arthritis, osteonecrosis, or fracture.

180 n among mice that did versus did not develop osteonecrosis (P < 0.0001); in mice with osteonecrosis,

181 der children, higher cumulative incidence of osteonecrosis (P = .02) and fracture (P = .06).

182 aring surface was evaluated subsequently for osteonecrosis-positive hips on both sets of images.

183 ated with white race, lower nadir CD4, prior osteonecrosis, prior fracture, and prior AIDS.

184 , lower baseline CD4, HCV coinfection, prior osteonecrosis, prior fracture, cardiovascular disease, a

185 osen based on putative mechanisms underlying osteonecrosis risk.

186 in situ death of isolated segments of bone (osteonecrosis) suggesting that glucocorticoid excess, th

187 , treatments are associated with symptomatic osteonecrosis that disproportionately affects adolescent

188 lop osteonecrosis (P < 0.0001); in mice with osteonecrosis, the associated vessels showed transmural

189 ween TBMES and osteonecrosis; in joints with osteonecrosis, this was comparable to background noise,

190 included allergic reactions to asparaginase, osteonecrosis, thrombosis, and disseminated fungal infec

191 To understand possible linkage of ischemic osteonecrosis to the ER stress, a surgery-induced animal

192 between glutamate receptor polymorphisms and osteonecrosis, using a large discovery cohort and 2 vali

193 y (grade 1-4) versus symptomatic (grade 2-4) osteonecrosis was 71.8% versus 17.6%, respectively.

194 imited and full examinations for presence of osteonecrosis was 98.9% (177 of 179 cases; kappa, 0.97).

195 In conclusion, osteonecrosis was associated with inherited variations n

196 Risk of osteonecrosis was associated with white race, lower nadi

197 The presence of osteonecrosis was determined by two radiologists.

198 Symptomatic osteonecrosis was diagnosed in 143 patients at 377 confi

199 No significant difference between TBMES and osteonecrosis was found for MTT (P = .09) and PF (P = .7

200 Extensive asymptomatic osteonecrosis was identified by early screening in 26 pa

201 tic osteonecrosis, and severe (grade 3 or 4) osteonecrosis was linked to poor dexamethasone clearance

202 Joint outcome of osteonecrosis was predicted solely by lesion size at dia

203 TBMES and osteonecrosis were compared statistically by using the M

204 about the risks of bisphosphonate-associated osteonecrosis were disseminated by national regulatory a

205 ineteen joints with TBMES and 17 joints with osteonecrosis were evaluated.

206 cally, persistent inflammation and extensive osteonecrosis were seen in group 4.